Deutsch English Français

Contact

EP3609504

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...

Extract from the Register of European Patents

EP About this file: EP3609504

EP3609504 - NOVEL OXABOROLE ANALOGS AND USES THEREOF [Right-click to bookmark this link]
Status	Request for examination was made Status updated on 17.01.2020 Database last updated on 06.07.2024
Former	The international publication has been made Status updated on 11.09.2018
Most recent event Tooltip	03.04.2024	New entry: Renewal fee paid
Applicant(s)	For all designated states Anacor Pharmaceuticals, LLC 66 Hudson Boulevard East New York, NY 10001-2192 / US
	For all designated states The Government of The United States, as Represented by The Secretary of The Army 521 Fraim Street Fort Detrick, Maryland 21702-5012 / US
	[2023/16]
Former [2022/33]	For all designated states Anacor Pharmaceuticals, LLC 235 East 42nd Street New York, NY 10017 / US
	For all designated states The Government of The United States, as Represented by The Secretary of The Army 521 Fraim Street Fort Detrick, Maryland 21702-5012 / US
Former [2021/35]	For all designated states Anacor Pharmaceuticals, Inc. 235 East 42nd Street New York, NY 10017 / US
	For all designated states The Government of The United States, as Represented by The Secretary of The Army 521 Fraim Street Fort Detrick, Maryland 21702-5012 / US
Former [2020/08]	For all designated states Anacor Pharmaceuticals, Inc. 1020 East Meadow Circle Palo Alto, CA 94303 / US
	For all designated states The Government of The United States, as Represented by The Secretary of The Army 521 Fraim Street Fort Detrick, Maryland 21702-5012 / US
Inventor(s)	01 / JACOBS, Robert Toms 1849 Old College Circle Wake Forest, North Carolina 27587 / US
	02 / LIU, Yang c/o Anacor Pharmaceuticals Inc. 1020 East Meadow Circle Palo Alto, California 94303 / US
	03 / SCIOTTI, Richard J. 4368 Morningwood Drive Olney, Maryland 20832 / US
	04 / ROBINSON, Stephen John c/o Drugs for Neglected Diseases Initiative 15 Chemin Louis-Dunant Geneva, 1202 / CH
	05 / MOWBRAY, Charles Eric c/o Drugs for Neglected Diseases Initiative 15 Chemin Louis-Dunant Geneva, 1202 / CH
	06 / SPEAKE, Jason D. c/o Scynexis, Inc. 3501 Tricenter Boulevard, Suite C Durham, NC 27713 / US
	07 / WHITLOCK, Gavin Alistair c/o Sandexis LLP 45 Queen Street Deal, Kent CT14 6EY / GB
	08 / LAUNAY, Delphine Françoise Monique c/o Drugs for Neglected Diseases Initiative 15 Chemin Louis-Dunant Geneva, 1202 / CH
	09 / GLOSSOP, Paul Alan c/o Sandexis LLP 45 Queen Street Deal, Kent CT14 6EY / GB
	[2020/08]
Representative(s)	Pfizer European Patent Department 23-25 avenue du Docteur Lannelongue 75668 Paris Cedex 14 / FR
	[N/P]
Former [2020/08]	J A Kemp LLP 14 South Square Gray's Inn London WC1R 5JJ / GB
Application number, filing date	18761407.8	01.03.2018
	[2020/08]
	WO2018US20464
Priority number, date	US201762465294P	01.03.2017 Original published format: US 201762465294 P
	[2020/08]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2018160845
	Date:	07.09.2018
	Language:	EN
	[2018/36]
	Type:	A1 Application with search report
	No.:	EP3609504
	Date:	19.02.2020
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 07.09.2018 takes the place of the publication of the European patent application.
	[2020/08]
Search report(s)	International search report - published on:	US	07.09.2018
	(Supplementary) European search report - dispatched on:	EP	01.02.2021
Classification	IPC:	C07F5/02, A61K31/69, A61P33/02	[2021/09]
	CPC:	A61P33/02 (EP,US); C07F5/025 (EP,US); Y02A50/30 (EP)
	Former IPC [2020/08]	A61K31/69, A61P33/02, C07F5/02
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/08]
Extension states	BA	13.12.2019
	ME	13.12.2019
Validation states	KH	13.12.2019
	MA	13.12.2019
	MD	13.12.2019
	TN	13.12.2019
Title	German:	NEUARTIGE OXABOROLANALOGA UND VERWENDUNGEN DAVON	[2020/08]
	English:	NOVEL OXABOROLE ANALOGS AND USES THEREOF	[2020/08]
	French:	NOUVEAUX ANALOGUES D'OXABOROLE ET UTILISATIONS DE CES DERNIERS	[2020/08]
Entry into regional phase	13.12.2019	National basic fee paid
	13.12.2019	Search fee paid
	13.12.2019	Designation fee(s) paid
	13.12.2019	Examination fee paid
Examination procedure	deleted	Deletion: Application deemed to be withdrawn, date of legal effect [2020/08]
	16.10.2019	Despatch of communication that the application is deemed to be withdrawn, reason: filing fee / search fee not paid in time [2020/08]
	13.12.2019	Examination requested [2020/08]
	13.08.2021	Amendment by applicant (claims and/or description)
Request for further processing for:	The application is deemed to be withdrawn due to non-payment of the search fee
	13.12.2019	Request for further processing filed
	13.12.2019	Full payment received (date of receipt of payment) Request granted
	22.01.2020	Decision despatched
	13.12.2019	Request for further processing filed
	13.12.2019	Full payment received (date of receipt of payment) Request granted
	22.01.2020	Decision despatched
	The application is deemed to be withdrawn due to non-payment of the filing fee
	13.12.2019	Request for further processing filed
	13.12.2019	Full payment received (date of receipt of payment) Request granted
	22.01.2020	Decision despatched
	The application is deemed to be withdrawn due to non-payment of the examination fee
	13.12.2019	Request for further processing filed
	13.12.2019	Full payment received (date of receipt of payment) Request granted
	22.01.2020	Decision despatched
	13.12.2019	Request for further processing filed
	13.12.2019	Full payment received (date of receipt of payment) Request granted
	22.01.2020	Decision despatched
	The application is deemed to be withdrawn due to non-payment of designation fees TR, SM, SK, SI, SE, RS, RO, PT, PL, NO, NL, MT, MK, MC, LV, LU, LT, IT, IS, IE, HU, HR, GR, GB, FR, FI, ES, EE, DK, DE, CZ, CY, CH, BG, BE, AT, AL
	13.12.2019	Request for further processing filed
	13.12.2019	Full payment received (date of receipt of payment) Request granted
	22.01.2020	Decision despatched
Fees paid	Renewal fee
	27.03.2020	Renewal fee patent year 03
	29.03.2021	Renewal fee patent year 04
	31.03.2022	Renewal fee patent year 05
	31.03.2023	Renewal fee patent year 06
	31.03.2024	Renewal fee patent year 07
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[I]WO2011019618 (ANACOR PHARMACEUTICALS INC [US], et al) [I] 1-13* the whole document *
	International search	[Y]US2011065725 (GARZYA VINCENZO [GB], et al) [Y] 1-5, 9-14 * ; paragraphs [0001]-[0004], [0012], [0019], [0216] *;
		[Y]WO2012145734 (UNIV OHIO STATE [US], et al) [Y] 1-5, 9-14* ; abstract; paragraph [0008], [00201], [00206] *;
		[Y]US2015344471 (CHATTERJEE ARNAB KUMAR [US], et al) [Y] 1, 6-8 * ; paragraphs [0012], [0014]-[0017], [0020], [0025], [0035]-[0036], [0054], [0064]-[0065], [0093], [0246] *;
		[Y]US2015361104 (AKAMA TSUTOMU [US], et al) [Y] 1-14 * ; paragraphs [0010], [0041], [0045], [0077], [0079], [0147], [0151], [0217], [0366] *

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.1.24; 35p